CV Sciences, Inc. (CVSI): Revenue
$13.79M
Year ended 2025-12-31
$12.74M
Trailing 12 months to 2026-06-30
-5.2%
3-year compound annual growth
-10.8%
5-year compound annual growth
+1.8%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.79M | -12.2% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $15.71M | -1.9% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $16.00M | -1.2% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $16.20M | -19.2% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $20.05M | -17.9% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $24.43M | -54.5% | 2022-04-04, From 2020-01-01 |
| 2019-12-31 | $53.70M | +11.3% | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $48.24M | +133.3% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $20.68M | +87.0% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $11.06M | -4.1% | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $11.53M | +13.1% | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $10.19M | +373.1% | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | $2.15M | n/a | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | $0 | n/a | 2014-03-28, From 2012-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $13.79M | -12.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $13.86M | -14.2% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $14.08M | +128.2% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $14.20M | +29.1% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $13.19M | n/a |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $13.11M | +29.8% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $13.00M | +85.7% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $12.45M | -25.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $12.14M | +73.4% |
Compare CVSI, PYXS, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗